Related Experiment Video
Updated: Aug 28, 2025
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
10:33
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
332
Current Status of 68Ga-Pentixafor in Solid Tumours
Bawinile Hadebe1,2, Machaba Michael Sathekge3, Colleen Aldous4
1Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Diagnostics (Basel, Switzerland)
|September 23, 2022
Summary
Ga-Pentixafor PET imaging visualizes CXCR4 receptor expression in tumors, aiding patient selection for targeted therapies. This radiotracer shows promise in both hematological malignancies and solid tumors, complementing existing imaging methods.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Chemokine receptor CXCR4 is overexpressed in various neoplasms, correlating with tumor invasion, metastasis, and aggressiveness.
- Ga-Pentixafor is an established radiotracer for imaging CXCR4 expression in hematological malignancies.
- Targeting CXCR4 demonstrates potential in enhancing chemosensitivity and inhibiting tumor progression.
Purpose of the Study:
- To review the literature on the potential applications of Ga-Pentixafor in solid tumors.
- To highlight Ga-Pentixafor's role in patient selection for CXCR4-targeted therapies.
- To discuss Ga-Pentixafor as a complementary imaging agent to 18F-FDG in solid tumors.
Main Methods:
- Literature review of studies investigating Ga-Pentixafor in solid tumors.
- Analysis of Ga-Pentixafor's utility in visualizing CXCR4 overexpression.
- Evaluation of Ga-Pentixafor's prognostic value and role in therapy selection.
Main Results:
- Ga-Pentixafor shows promise for non-invasively imaging CXCR4 expression in solid tumors.
- It can provide prognostic information and aid in selecting patients for CXCR4-targeted therapies.
- Ga-Pentixafor complements 18F-FDG imaging in solid tumors.
Conclusions:
- Ga-Pentixafor is a valuable radiotracer for assessing CXCR4 expression in solid tumors.
- It facilitates patient stratification for novel CXCR4-targeted therapies.
- Further research into Ga-Pentixafor's applications in solid tumors is warranted.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)